Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bub1b siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
Bub1b siRNA is a research-grade small interfering RNA (siRNA) reagent designed to silence the expression of the BUB1B gene (also known as BubR1 or BUB1 Mitotic Checkpoint Serine/Threonine Kinase B). BUB1B is an essential component of the spindle assembly checkpoint (SAC) that regulates chromosome alignment and segregation during mitosis. By knocking down BUB1B expression, this siRNA disrupts the mitotic checkpoint, leading to cell cycle arrest, mitotic catastrophe, and apoptosis in rapidly proliferating cells. Preclinical studies have demonstrated its utility in inhibiting cancer cell proliferation and overcoming drug resistance in various oncology models, including breast cancer (particularly triple-negative breast cancer), multiple myeloma, and gastric cancer. It is widely available from multiple life-science reagent suppliers for research use only.
- Other names
- BUB1 mitotic checkpoint serine/threonine kinase B siRNABUB1B siRNABUB-1B siRNABUB 1B siRNABubR1 siRNABubR-1 siRNABubR 1 siRNA
02
Targets
BUB1B (Mitotic checkpoint serine/threonine-protein kinase BUB1 beta)
Beyond the preview
Go deeper on Bub1b siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bub1b siRNA.